{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T04:44:26Z","timestamp":1794545066924,"version":"4.9.1"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,3,23]],"date-time":"2024-03-23T00:00:00Z","timestamp":1711152000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,3,23]],"date-time":"2024-03-23T00:00:00Z","timestamp":1711152000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BioDrugs"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1007\/s40259-024-00655-4","type":"journal-article","created":{"date-parts":[[2024,3,23]],"date-time":"2024-03-23T10:01:47Z","timestamp":1711188107000},"page":"331-339","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Additional Data in Expanded Patient Populations and New Indications Support the Practice of Biosimilar-to-Biosimilar Switching"],"prefix":"10.1007","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8758-0890","authenticated-orcid":false,"given":"Hillel P.","family":"Cohen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfram","family":"Bodenmueller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,23]]},"reference":[{"key":"655_CR1","unstructured":"US Food and Drug Administration. Biosimilars. 2023. https:\/\/www.fda.gov\/drugs\/therapeutic-biologics-applications-bla\/biosimilars. Accessed 12 Dec 2023."},{"key":"655_CR2","unstructured":"Generics and Biosimilars Initiative. Biosimilars approved in Europe. 2023. https:\/\/www.gabionline.net\/biosimilars\/general\/biosimilars-approved-in-europe. Accessed 12 Dec 2023."},{"key":"655_CR3","unstructured":"US Food and Drug Administration. Biosimilar product information. 2023. https:\/\/www.fda.gov\/drugs\/biosimilars\/biosimilar-product-information. Accessed 12 Dec 2023."},{"key":"655_CR4","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1007\/s40259-022-00546-6","volume":"36","author":"HP Cohen","year":"2022","unstructured":"Cohen HP, Hachaichi S, Bodenmueller W, Kvien TK, Danese S, Blauvelt A. Switching from one biosimilar to another biosimilar of the same reference biologic: a systematic review of studies. BioDrugs. 2022;36:625\u201337.","journal-title":"BioDrugs"},{"key":"655_CR5","doi-asserted-by":"crossref","unstructured":"European Medicines Agency and Heads of Medicines Agencies. EMA\/627319\/2022 Statement on the scientific rationale supporting interchangeability of biosimilar medicines in the EU. 2023. https:\/\/www.ema.europa.eu\/en\/documents\/public-statement\/statement-scientific-rationale-supporting-interchangeability-biosimilar-medicines-eu_en.pdf. Accessed 29 Nov 2023.","DOI":"10.1136\/ejhpharm-2022-003571"},{"key":"655_CR6","doi-asserted-by":"crossref","unstructured":"European Medicines Agency. Q&A on the statement on the scientific rationale supporting interchangeability of biosimilar medicines in the EU. 2023. https:\/\/www.ema.europa.eu\/en\/documents\/other\/qa-statement-scientific-rationale-supporting-interchangeability-biosimilar-medicines-eu_en.pdf. Accessed 29 Nov 2023.","DOI":"10.1136\/ejhpharm-2022-003571"},{"key":"655_CR7","doi-asserted-by":"publisher","first-page":"e0292231","DOI":"10.1371\/journal.pone.0292231","volume":"18","author":"TM Herndon","year":"2023","unstructured":"Herndon TM, Ausin C, Brahme NN, et al. Safety outcomes when switching between biosimilars and reference biologics: a systematic review and meta-analysis. PLoS ONE. 2023;18:e0292231.","journal-title":"PLoS ONE"},{"key":"655_CR8","unstructured":"Brahme N, Skibinski S, Ikenberry S. FDA Drug Topics: Biosimilars: a review of scientific, regulatory, and clinical considerations for health care providers. 2023. https:\/\/www.fda.gov\/media\/169599\/download. Accessed 29 Nov 2023."},{"key":"655_CR9","doi-asserted-by":"publisher","first-page":"917814","DOI":"10.3389\/fphar.2022.917814","volume":"13","author":"E Allocati","year":"2022","unstructured":"Allocati E, Godman B, Gobbi M, Garattini S, Banzi R. Switching among biosimilars: a review of clinical evidence. Front Pharmacol. 2022;13:917814.","journal-title":"Front Pharmacol"},{"key":"655_CR10","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1007\/s43441-022-00473-2","volume":"57","author":"R Lasala","year":"2023","unstructured":"Lasala R, Abrate P, Zovi A, Santoleri F. Safety and effectiveness of multiple switching between originators and biosimilars: literature review and status report on interchangeability. Ther Innov Regul Sci. 2023;57:352\u201364.","journal-title":"Ther Innov Regul Sci."},{"key":"655_CR11","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1093\/jcag\/gwad027","volume":"7","author":"S Meade","year":"2023","unstructured":"Meade S, Squirell E, Hoang TT, Chow J, Rosenfeld G. An update on anti-TNF biosimilar switching: real-world clinical effectiveness and safety. J Can Assoc Gastroenterol. 2023;7:30\u201345.","journal-title":"J Can Assoc Gastroenterol."},{"key":"655_CR12","doi-asserted-by":"publisher","first-page":"441","DOI":"10.3390\/cells10020441","volume":"10","author":"BJM Peters","year":"2021","unstructured":"Peters BJM, Bhatoe A, Vorselaars ADM, Veltkamp M. Switching to an infliximab biosimilar was safe and effective in Dutch sarcoidosis patients. Cells. 2021;10:441.","journal-title":"Cells"},{"key":"655_CR13","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1002\/ueg2.12357","volume":"11","author":"B Gros","year":"2023","unstructured":"Gros B, Plevris N, Constantine-Cooke N, et al. Multiple infliximab biosimilar switches appear to be safe and effective in a real-world inflammatory bowel disease cohort. United Eur Gastroenterol J. 2023;11:179\u201388.","journal-title":"United Eur Gastroenterol J."},{"key":"655_CR14","doi-asserted-by":"publisher","first-page":"336","DOI":"10.48095\/ccgh2023336","volume":"77","author":"J Reissigov\u00e1","year":"2023","unstructured":"Reissigov\u00e1 J, \u010cern\u00e1 K, Luk\u00e1\u0161 M Jr, et al. Switch from biosimilar infliximab CT-P13 to biosimilar infliximab SB-2 in the long-term maintenance therapy in IBD patients: prospective observational study. Gastroent Hepatol. 2023;77:336\u201341.","journal-title":"Gastroent Hepatol."},{"issue":"Suppl. 8","key":"655_CR15","first-page":"1029","volume":"11","author":"G Privitera","year":"2023","unstructured":"Privitera G, Melita E, Monastero L, et al. PP0855 Infliximab biosimilar switch is safe and effective, it does not have major psychological implications and does not affet pharmacokinetics in a large cohort of patients with IBD. United Eur Gastroenterol J. 2023;11(Suppl. 8):1029.","journal-title":"United Eur Gastroenterol J"},{"key":"655_CR16","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1016\/j.dld.2022.07.004","volume":"54","author":"L Lontai","year":"2022","unstructured":"Lontai L, Gonczi L, Balogh F, et al. Non-medical switch from the originator to biosimilar and between biosimilars of adalimumab in inflammatory bowel disease: a prospective, multicentre study. Dig Liver Dis. 2022;54:1639\u201345.","journal-title":"Dig Liver Dis"},{"key":"655_CR17","first-page":"613","volume":"41","author":"R Scrivo","year":"2023","unstructured":"Scrivo R, Castellani C, Mancuso S, et al. Effectiveness of non-medical switch from adalimumab bio-originator to SB5 biosimilar and from ABP501 adalimumab biosimilar to SB5 biosimilar in patients with chronic inflammatory arthropathies: a monocentric observational study. Clin Exp Rheumatol. 2023;41:613\u20139.","journal-title":"Clin Exp Rheumatol"},{"key":"655_CR18","doi-asserted-by":"publisher","first-page":"6839","DOI":"10.3390\/jcm12216839","volume":"12","author":"M Vernero","year":"2023","unstructured":"Vernero M, Bezzio C, Ribaldone DG, et al. Efficacy and safety of adalimumab biosimilar GP2017 in patients with inflammatory bowel disease. J Clin Med. 2023;12:6839.","journal-title":"J Clin Med"},{"issue":"Suppl. 1","key":"655_CR19","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1136\/annrheumdis-2022-eular.1828","volume":"81","author":"S Parisi","year":"2022","unstructured":"Parisi S, Becciolini A, Ditto MC, et al. AB0341 Efficacy and drug survival after multiple-switching from adalimumab originator to the biosimilars ABP501 and SB5: a real-life study. Ann Rheum Dis. 2022;81(Suppl. 1):1295\u20136.","journal-title":"Ann Rheum Dis"},{"key":"655_CR20","doi-asserted-by":"publisher","first-page":"e002560","DOI":"10.1136\/rmdopen-2022-002560","volume":"8","author":"H Nabi","year":"2022","unstructured":"Nabi H, Hendricks O, Jensen DV, et al. Infliximab biosimilar-to-biosimilar switching in patients with inflammatory rheumatic disease: clinical outcomes in real-world patients from the DANBIO registry. RMD Open. 2022;8:e002560.","journal-title":"RMD Open"},{"key":"655_CR21","doi-asserted-by":"publisher","first-page":"175628482211456","DOI":"10.1177\/17562848221145654","volume":"16","author":"Y Bouhnik","year":"2023","unstructured":"Bouhnik Y, Fautrel B, Beaugerie L, et al. PERFUSE: a French non-interventional study of patients with inflammatory bowel disease receiving infliximab biosimilar SB2: a 12-month analysis. Therap Adv Gastroenterol. 2023;16:17562848221145654.","journal-title":"Therap Adv Gastroenterol."},{"key":"655_CR22","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1007\/s40265-021-01610-1","volume":"81","author":"E Mysler","year":"2021","unstructured":"Mysler E, Azevedo VF, Danese S, et al. Biosimilar-to-biosimilar switching: what is the rationale and current experience? Drugs. 2021;81:1859\u201379.","journal-title":"Drugs"},{"key":"655_CR23","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s40259-017-0210-0","volume":"31","author":"P Kurki","year":"2017","unstructured":"Kurki P, van Aerts L, Wolff-Holz E, et al. Interchangeability of biosimilars: a European perspective. BioDrugs. 2017;31:83\u201391.","journal-title":"BioDrugs"},{"key":"655_CR24","doi-asserted-by":"publisher","first-page":"820755","DOI":"10.3389\/fmed.2022.820755","volume":"9","author":"L Barbier","year":"2022","unstructured":"Barbier L, Mbuaki A, Simoens S, et al. Regulatory information and guidance on biosimilars and their use across Europe: a call for strengthened one voice messaging. Front Med (Lausanne). 2022;9:820755.","journal-title":"Front Med (Lausanne)."},{"key":"655_CR25","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1007\/s40265-021-01601-2","volume":"81","author":"P Kurki","year":"2021","unstructured":"Kurki P, Barry S, Bourges I, et al. Safety, immunogenicity and interchangeability of biosimilar monoclonal antibodies and fusion proteins: a regulatory perspective. Drugs. 2021;81:1881\u201396.","journal-title":"Drugs"},{"key":"655_CR26","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1002\/cpt.1836","volume":"108","author":"L Barbier","year":"2020","unstructured":"Barbier L, Ebbers HC, Declerck P, Simoens S, Vulto AG, Huys I. The efficacy, safety, and immunogenicity of switching between reference biopharmaceuticals and biosimilars: a systematic review. Clin Pharmacol Ther. 2020;108:734\u201355.","journal-title":"Clin Pharmacol Ther"},{"key":"655_CR27","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1007\/s40265-018-0881-y","volume":"78","author":"HP Cohen","year":"2018","unstructured":"Cohen HP, Blauvelt A, Rifkin RM, Danese S, Gokhale SB, Woollett G. Switching reference medicines to biosimilars: a systematic literature review of clinical outcomes. Drugs. 2018;78:463\u201378.","journal-title":"Drugs"},{"key":"655_CR28","doi-asserted-by":"publisher","first-page":"5956","DOI":"10.1038\/s41598-021-85563-1","volume":"11","author":"SAM Urru","year":"2021","unstructured":"Urru SAM, Spila Alegiani S, Guella A, Traversa G, Campomori A. Safety of switching between rituximab biosimilars in onco-hematology. Sci Rep. 2021;11:5956.","journal-title":"Sci Rep"},{"key":"655_CR29","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1111\/apt.16312","volume":"53","author":"N Trystram","year":"2021","unstructured":"Trystram N, Abitbol V, Tannoury J, et al. Outcomes after double switching from originator Infliximab to biosimilar CT-P13 and biosimilar SB2 in patients with inflammatory bowel disease: a 12-month prospective cohort study. Aliment Pharmacol Ther. 2021;53:887\u201399.","journal-title":"Aliment Pharmacol Ther"},{"key":"655_CR30","doi-asserted-by":"publisher","first-page":"otab022","DOI":"10.1093\/crocol\/otab022","volume":"3","author":"N Khan","year":"2021","unstructured":"Khan N, Patel D, Pernes T, et al. The efficacy and safety of switching from originator infliximab to single or double switch biosimilar among a nationwide cohort of inflammatory bowel disease patients. Crohns Colitis. 2021;3:otab022.","journal-title":"Crohns Colitis"},{"key":"655_CR31","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1111\/apt.16497","volume":"54","author":"RP Luber","year":"2021","unstructured":"Luber RP, O\u2019Neill R, Singh S, et al. An observational study of switching infliximab biosimilar: no adverse impact on inflammatory bowel disease control or drug levels with first or second switch. Aliment Pharmacol Ther. 2021;54:678\u201388.","journal-title":"Aliment Pharmacol Ther"},{"key":"655_CR32","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1111\/cts.13131","volume":"15","author":"S Mazza","year":"2022","unstructured":"Mazza S, Piazza OSN, Conforti FS, et al. Safety and clinical efficacy of the double switch from originator infliximab to biosimilars CT-P13 and SB2 in patients with inflammatory bowel diseases (SCESICS): a multicenter cohort study. Clin Transl Sci. 2022;15:172\u201381.","journal-title":"Clin Transl Sci"},{"key":"655_CR33","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1093\/ibd\/izab099","volume":"28","author":"J Hanzel","year":"2022","unstructured":"Hanzel J, Jansen JM, Ter Steege RWF, Gecse KB, D\u2019Haens GR. Multiple switches from the originator infliximab to biosimilars is effective and safe in inflammatory bowel disease: a prospective multicenter cohort study. Inflamm Bowel Dis. 2022;28:495\u2013501.","journal-title":"Inflamm Bowel Dis"},{"key":"655_CR34","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1097\/MEG.0000000000001988","volume":"32","author":"R Lovero","year":"2021","unstructured":"Lovero R, Losurdo G, La Fortezza RF, et al. Safety and efficacy of switching from infliximab biosimilar CT-P13 to infliximab biosimilar SB2 in patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2021;32:201\u20137.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"655_CR35","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1093\/ibd\/izaa036","volume":"27","author":"FS Macaluso","year":"2021","unstructured":"Macaluso FS, Fries W, Viola A, et al. The SPOSIB SB2 Sicilian Cohort: safety and effectiveness of infliximab biosimilar SB2 in inflammatory bowel diseases, including multiple switches. Inflamm Bowel Dis. 2021;27:182\u20139.","journal-title":"Inflamm Bowel Dis"},{"key":"655_CR36","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1111\/bjd.19013","volume":"183","author":"P Gisondi","year":"2020","unstructured":"Gisondi P, Virga C, Piaserico S, et al. Switching from one infliximab biosimilar (CT-P13) to another infliximab biosimilar (SB2) in patients with chronic plaque psoriasis. Br J Dermatol. 2020;183:397\u20138.","journal-title":"Br J Dermatol"},{"key":"655_CR37","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1016\/j.semarthrit.2020.02.007","volume":"50","author":"A Lauret","year":"2020","unstructured":"Lauret A, Molto A, Abitbol V, et al. Effects of successive switches to different biosimilars infliximab on immunogenicity in chronic inflammatory diseases in daily clinical practice. Semin Arthritis Rheum. 2020;50:1449\u201356.","journal-title":"Semin Arthritis Rheum"},{"key":"655_CR38","doi-asserted-by":"publisher","first-page":"1248526","DOI":"10.1155\/2023\/1248526","volume":"2023","author":"C Harris","year":"2023","unstructured":"Harris C, Harris RJ, Young D, et al. Clinical outcomes and patient experience of biosimilar to biosimilar infliximab switching in patients with inflammatory bowel disease: a prospective, single-centre, phase IV interventional study with a nested qualitative study. GastroHep. 2023;2023:1248526.","journal-title":"GastroHep."},{"key":"655_CR39","doi-asserted-by":"publisher","first-page":"rkad031","DOI":"10.1093\/rap\/rkad031","volume":"7","author":"B Fautrel","year":"2023","unstructured":"Fautrel B, Bouhnik Y, Dieude P, et al. Real-world evidence of the use of the infliximab biosimilar SB2: data from the PERFUSE study. Rheumatol Adv Pract. 2023;7:rkad031.","journal-title":"Rheumatol Adv Pract."},{"key":"655_CR40","doi-asserted-by":"publisher","first-page":"3387","DOI":"10.3390\/jcm10153387","volume":"10","author":"DG Ribaldone","year":"2021","unstructured":"Ribaldone DG, Tribocco E, Rosso C, et al. Switching from biosimilar to biosimilar adalimumab, including multiple switching, in Crohn\u2019s disease: a prospective study. J Clin Med. 2021;10:3387.","journal-title":"J Clin Med"},{"key":"655_CR41","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1093\/ecco-jcc\/jjab100","volume":"15","author":"L Derikx","year":"2021","unstructured":"Derikx L, Dolby HW, Plevris N, et al. Effectiveness and safety of adalimumab biosimilar SB5 in inflammatory bowel disease: outcomes in originator to SB5 switch, double biosimilar switch and bio-naive SB5 observational cohorts. J Crohns Colitis. 2021;15:2011\u201321.","journal-title":"J Crohns Colitis"},{"key":"655_CR42","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s40259-021-00485-8","volume":"35","author":"S Piaserico","year":"2021","unstructured":"Piaserico S, Conti A, Messina F, et al. Cross-switch from etanercept originator to biosimilar SB4 and to GP2015 in patients with chronic plaque psoriasis. BioDrugs. 2021;35:469\u201371.","journal-title":"BioDrugs"},{"key":"655_CR43","doi-asserted-by":"publisher","first-page":"17597","DOI":"10.1177\/1759720X221119593","volume":"14","author":"U Kiltz","year":"2022","unstructured":"Kiltz U, Tsiami S, Baraliakos X, Andreica I, Kiefer D, Braun J. Effectiveness and safety of a biosimilar-to-biosimilar switch of the TNF inhibitor etanercept in patients with chronic inflammatory rheumatic diseases. Ther Adv Musculoskelet Dis. 2022;14:17597.","journal-title":"Ther Adv Musculoskelet Dis."},{"key":"655_CR44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0016-5085(21)01042-8","volume":"160","author":"SI Siakavellas","year":"2021","unstructured":"Siakavellas SI, Barrett RA, Plevris N, et al. 610 Both single and multiple switching between infliximab biosimilars can be safe and effective in inflammatory bowel disease (IBD): real world outcomes from the Edinburgh IBD unit. Gastroenterology. 2021;160:1\u2013120.","journal-title":"Gastroenterology"},{"issue":"Suppl. 1","key":"655_CR45","first-page":"A98","volume":"27","author":"R O\u2019Neill","year":"2020","unstructured":"O\u2019Neill R, Singh S, Luber R. 4CPS-108 a review of infliximab biosimilar to biosimilar switch: Remsima to Flixabi. Eur J Hosp Pharm. 2020;27(Suppl. 1):A98.","journal-title":"Eur J Hosp Pharm"},{"key":"655_CR46","doi-asserted-by":"crossref","first-page":"A92","DOI":"10.1136\/gutjnl-2020-322630","volume":"70","author":"A Mott","year":"2021","unstructured":"Mott A, Mott A, Taherzadeh N, et al. PMO-29 Switching between infliximab biosimilars: experience from two inflammatory bowel disease centres. Gut. 2021;70:A92.","journal-title":"Gut"},{"key":"655_CR47","first-page":"474","volume":"28","author":"F Cunningham","year":"2019","unstructured":"Cunningham F, Shurmunov A, Dong D, Salone C, Zacher J, Glassman P. 977 Biosimilar safety dashboard to assess switching in veterans. Pharmacoepidemiol Drug Saf. 2019;28:474\u20135.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"655_CR48","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1136\/annrheumdis-2021-eular.1742","volume":"80","author":"S Gall","year":"2021","unstructured":"Gall S, Kiltz U, Kobylinski T, et al. POS0301 No major differences between patients with chronic inflammatory rheumatic disease who underwent mono- or multiswitching of biosimilars in routine care (PERCEPTION study). Ann Rheum Dis. 2021;80:376.","journal-title":"Ann Rheum Dis"}],"container-title":["BioDrugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-024-00655-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40259-024-00655-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-024-00655-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,27]],"date-time":"2024-04-27T17:13:10Z","timestamp":1714237990000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40259-024-00655-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,23]]},"references-count":48,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["655"],"URL":"https:\/\/doi.org\/10.1007\/s40259-024-00655-4","relation":{},"ISSN":["1173-8804","1179-190X"],"issn-type":[{"value":"1173-8804","type":"print"},{"value":"1179-190X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,23]]},"assertion":[{"value":"27 February 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Financial assistance for editorial support and Open Access charges was provided by Sandoz Deutschland\/Hexal AG.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Hillel P. Cohen is an employee of Sandoz Inc. Wolfram Bodenmueller is an employee of Sandoz Deutschland\/Hexal AG. Sandoz manufactures and markets multiple biosimilars worldwide, including several discussed in this publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest\/Competing Interests"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"All publications included in this systematic review are available in the public domain.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"HPC developed the concept for this publication, conducted the literature reviews and drafted the initial manuscript. WB reviewed and revised the clinical data summaries. Both authors participated in the writing of the publication and approved the final manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}